# Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

> **NCT05206357** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 17 (actual)

## Conditions studied

- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Epcoritamab

## Key facts

- **NCT ID:** NCT05206357
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-04
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206357, "Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05206357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*